New drug combo aims to outperform standard chemo in lung cancer
NCT ID NCT07464327
First seen Mar 13, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This phase 3 study tests whether a new drug (HS-20093) combined with adebrelimab works better than the standard chemo docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has no targetable gene changes. About 450 adults who have already received prior treatment will be randomly assigned to one of the two treatments. The main goals are to see if the combination slows cancer growth and helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.